MYC and Miyoshi myopathy: Interestingly, the combination of anti-IL17RA and anti-IL-17A, did not significantly impact the disease (Fig. 6b), and treatment with only anti-IL5 antibodies, while associated with reduced BM accrual of eosinophils (Supplementary Fig. 10c, d), neither impacted disease progression in our MM models (Fig. 6b and Supplementary Fig. 10a), nor affected Th17 accrual in the BM of t-Vk*MYC MM mice (Supplementary Fig. 10b).